Center for Health Policy and Research; Clinical Pharmacy Services; Commonwealth Medicine
Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences | Virus Diseases
An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.
Hepatitis C, Harvoni, ledipasvir, sofosbuvir, HCV genotype 1
Rights and Permissions
© 2017 University of Massachusetts Medical School
2017 Academy of Managed Care and Specialty Pharmacy Annual Conference
Kouris, George; Hydery, Tasmina; Greenwood, Bonnie C.; Lavitas, Pavel; Alper, Caroline J.; Price, Mylissa K.; Clements, Karen M.; Lenz, Kimberly J.; and Jeffrey, Paul L., "Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population" (2017). Commonwealth Medicine Publications. 38.